EXENATIDE SYNTHETIC - Generic Drug Details

What are the generic sources for exenatide synthetic and what is the scope of freedom to operate?

Exenatide synthetic is the generic ingredient in five branded drugs marketed by Astrazeneca Ab and Amneal, and is included in four NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Exenatide synthetic has three hundred and thirty-nine patent family members in forty-nine countries.

Two suppliers are listed for this compound.

Summary for EXENATIDE SYNTHETIC

International Patents:	339
US Patents:	7
Tradenames:	5
Applicants:	2
NDAs:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	7
Patent Applications:	228
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXENATIDE SYNTHETIC
DailyMed Link:	EXENATIDE SYNTHETIC at DailyMed

Recent Clinical Trials for EXENATIDE SYNTHETIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Karolinska Institutet	Phase 2
Center for Neurology, Stockholm	Phase 2
Monash University	Phase 2

See all EXENATIDE SYNTHETIC clinical trials

Pharmacology for EXENATIDE SYNTHETIC

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for EXENATIDE SYNTHETIC

A10BJ	Glucagon-like peptide-1 (GLP-1) analogues
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for EXENATIDE SYNTHETIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BYETTA	Injection	exenatide synthetic	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe	021773	1	2014-06-11

US Patents and Regulatory Information for EXENATIDE SYNTHETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	8,906,851*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	6,515,117*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	9,884,092*PED				Y
Amneal	EXENATIDE SYNTHETIC	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	206697-001	Nov 19, 2024		RX	No	Yes
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	8,329,648*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	8,906,851*PED				Y

Expired US Patents for EXENATIDE SYNTHETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012	6,872,700
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014	6,936,590
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014	6,495,164
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012	6,479,065
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,872,700
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017	6,956,026
Astrazeneca Ab	BYETTA	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	021773-002	Apr 28, 2005	6,956,026

International Patents for EXENATIDE SYNTHETIC

Country	Patent Number	Title	Estimated Expiration
Serbia	53638	KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
European Patent Office	1506211	C-ARYL GLUCOSIDES EN TANT QU'INHIBITEURS DE SGLT-2 ET METHODE CORRESPONDANTE (C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD)
Eurasian Patent Organization	020299
Cyprus	1122010
World Intellectual Property Organization (WIPO)	2008002824
Portugal	2069374
Japan	5693817

Supplementary Protection Certificates for EXENATIDE SYNTHETIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	SPC/GB14/050	United Kingdom		PRODUCT NAME: A COMBINATION OF DAPAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METFORMIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/900 20140121
1506211	18/2013	Austria		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211	C20140021 00131	Estonia		PRODUCT NAME: DAPAGLIFLOSIIN/METFORMIIN;REG NO/DATE: K(2014)308 (LOPLIK) 21.01.2014
1734971	122012000028	Germany		PRODUCT NAME: BYDUREON-EXENATIDE; REGISTRATION NO/DATE: EU/1/11/696/001-002 20110617
1506211	C 2014 029	Romania		PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116
2139494	2020C/533	Belgium		PRODUCT NAME: QTERN -SAXAGLIPTINE ET DAPAGLIFLOZINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1108 20160719
1734971	C01734971/01	Switzerland		PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: SWISSMEDIC 61629 17.02.2012

Exenatide Synthetic: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the commercial footprint of synthetic exenatide?

Synthetic exenatide is the active ingredient in branded and follow-on GLP-1 receptor agonist (GLP-1 RA) products for type 2 diabetes. The core branded product is Byetta (exenatide twice daily) and the longer-acting portfolio member is Bydureon/Bydureon BC (exenatide extended release). In parallel, multiple generics and authorized follow-ons have competed in many markets.

Market structure (U.S. example, practical view):

• Brand exenatide (history): Byetta and Bydureon/Bydureon BC.
• Follow-on entry: Generics and authorized brands of exenatide (formulation-dependent).
• Class-level pressure: Stronger once-weekly GLP-1 RAs (and then dual agonists) displaced parts of exenatide’s demand curve in later years.

Demand drivers that moved exenatide’s trajectory:

• Efficacy and tolerability comparisons within GLP-1 RA class: Patients and prescribers shifted toward agents with better weight outcomes and/or simpler dosing, narrowing exenatide’s addressable pool.
• Payer formulary management: Step therapy, prior authorization, and preferred tiering increasingly favored higher-efficacy agents, compressing utilization of older GLP-1 RAs.
• Net pricing erosion: Competitive entry and class substitution reduced list-to-net realization.

How do market dynamics shape exenatide pricing and utilization?

The exenatide synthetic market behaves like a mature, competitively substituted diabetes franchise. Key dynamics:

• Dosing convenience gap: Exenatide exists as twice-daily and extended-release formats. Real-world preference moved toward once-weekly regimens and then higher-tier agents, reducing incremental demand.
• Formulary gatekeeping: Medicare Part D and commercial payers increasingly standardized preferred GLP-1 RAs; exenatide increasingly sat outside top tiers after broader diffusion of newer agents.
• Patent and exclusivity endgames: As exclusivity expired across geographies, generic availability triggered price compression and volume reallocation.
• Competition cascade: GLP-1 RA competition accelerated when next-generation agents expanded indications and uptake, pulling patients away from older GLP-1 RAs.

Competitive positioning inside the GLP-1 RA stack

Exenatide’s competitive disadvantage is primarily comparative rather than absolute:

• Many newer GLP-1 RAs improved the risk-benefit profile versus older agents and improved perceived outcomes in weight and glycemic durability.
• Once-weekly convenience reduced adherence friction relative to twice-daily dosing.

Product-level implications

• Byetta (twice daily): Typically more exposed to substitution due to dosing frequency.
• Bydureon (extended release): Reduced dosing burden but remained exposed to preference for newer once-weekly and higher-efficacy alternatives.

What has been the financial trajectory for exenatide synthetic?

Exenatide’s financial path follows a mature pattern:

1. Peak-to-decline from class competition as newer GLP-1 RAs scaled.
2. Net sales compression driven by:
   • generic competition,
   • payer preference shifts,
   • and broader diabetes treatment algorithm changes.
3. Stabilization pockets in markets and segments where older GLP-1 RAs retained favorable formulary access.

Institutional reality: tracking branded and non-branded lines

Financial trajectory must be evaluated at two levels:

• Branded exenatide net sales (Byetta, Bydureon/Bydureon BC) during the exclusivity window and immediate decline afterward.
• Total exenatide category sales (including generics/follow-ons) which can show slower erosion than branded-only revenue because follow-on volume offsets part of the branded decline, even as pricing drops.

What typically happens to revenue after generic and class displacement

For exenatide, the historical pattern of mature injectables is:

• Units may hold up longer than revenue due to follow-on substitution.
• Revenue and operating income contract faster than volume due to net price erosion and manufacturing margin mix changes.

How do regulatory and legal timelines influence the cash curve?

Exenatide’s market behavior is shaped by:

• Exclusivity windows for innovator formulations (brand-specific).
• Generic entry timing driven by ANDA approvals and patent litigation outcomes (where applicable).
• Label expansions and switching rules that affect how payers re-underwrite preferred tier decisions.

A key practical point: exenatide is a mature molecule; most remaining growth levers are formulation and competitive differentiation, not mechanism novelty.

What do demand and access trends imply for near-term outlook?

Near-term demand for exenatide synthetic is driven by:

• Clinical substitution patterns: prescribers consolidate within preferred, higher-efficacy agents, leaving exenatide to “niche retention” or patients already stable on therapy.
• Payer constraints: preferred formulary lists are less likely to expand for an older GLP-1 RA absent compelling advantages.
• Wholesale and pharmacy channel economics: mature products tend to experience cyclical rebate and discount pressures that further compress net prices.

Category-level growth is possible, but branded growth is structurally harder

• Category volume can persist through generic substitution.
• Branded revenue growth is structurally constrained by:
  • payer switching,
  • class-level preferences,
  • and competitive intensity.

Where are the revenue pinch points?

For exenatide specifically, the pinch points typically occur at:

• Net pricing: list price is less informative than rebate and discount structure under formulary pressure.
• Formulary access: loss of “preferred” status changes prescribing behavior quickly.
• Injection device and tolerability perception: among older injectables, patient experience can amplify switching even without major label changes.
• Head-to-head perception vs newer agents: even when clinical differences are nuanced, payer and prescriber beliefs can drive faster adoption away from exenatide.

What financial metrics should be monitored to judge trajectory?

To model and monitor exenatide’s financial trajectory, the most actionable KPIs are:

• Branded net sales (Byetta and Bydureon/Bydureon BC lines, separately when available).
• Total prescriptions and TRx for exenatide-containing products by channel (retail vs specialty).
• Share of GLP-1 RA prescriptions relative to once-weekly agents.
• Gross-to-net (GxN) trend as competition intensifies.
• Average selling price proxy by payer mix and rebate evolution.
• Generic penetration of exenatide within the GLP-1 RA segment.

How does the competitive landscape shift the expected cash profile?

The GLP-1 RA class shifted from “available options” to “preferred options.” In that regime:

• Older GLP-1 RAs like exenatide typically become value-retention products rather than growth engines.
• Cash profiles become dominated by:
  • conversion of remaining patients already on therapy,
  • defense of formulary access in specific plans or markets,
  • and generic volume economics.

Comparative competitive set effects

As newer GLP-1 RAs and dual agonists expanded market share, exenatide’s expected profile tightened:

• Lower probability of market expansion
• Higher probability of gradual share drift
• Ongoing pricing pressure from follow-on entries

What is the bottom-line financial trajectory summary?

Synthetic exenatide’s financial trajectory is consistent with a mature branded injectable that faced accelerated substitution within GLP-1 RAs. The expected arc is:

• Branded decline after exclusivity and class preference shift
• Partial offset via follow-on volume
• Sustained net revenue compression due to payer-driven discounting and competitive tiering

Key Takeaways

• Synthetic exenatide is a mature GLP-1 RA franchise dominated by branded decline and follow-on substitution.
• Market dynamics are primarily driven by payer formulary preference, dosing convenience competition, and class-level efficacy perception shifts.
• Financial trajectory is characterized by net sales erosion for branded products, with partial stabilization at the category level from generics and authorized follow-ons.
• The key performance indicators for ongoing assessment are branded net sales, category TRx share within GLP-1 RAs, generic penetration, and gross-to-net pressure.
• Near-term outlook is retention-focused, not growth-engine focused, unless formulation or access advantages materially change payer behavior.

FAQs

1) What role does dosing frequency play in exenatide’s market dynamics?

Twice-daily regimens face faster substitution to once-weekly options, while extended-release versions reduce but do not eliminate preference pressure.

2) Why do payers tend to de-prioritize older GLP-1 RAs like exenatide?

Payer formularies increasingly standardize around preferred agents that meet higher-efficacy and/or weight-related expectations, tightening access to older class members.

3) How do generics affect exenatide synthetic revenue?

Generic entry typically compresses net pricing quickly. Category volume can remain but branded revenue usually declines faster than units.

4) What metrics best indicate whether exenatide is gaining or losing share?

TRx share within GLP-1 RAs, prescription mix by channel, and payer-driven gross-to-net trends.

5) Does exenatide have any credible growth path left?

Growth is most likely via formulary retention and niche persistence rather than broad expansion, unless a formulation or access shift changes payer and prescriber selection.

---

References

[1] FDA. Exenatide drug label information (Byetta, Bydureon/Bydureon BC). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] Eli Lilly and Company. Byetta (exenatide) and Bydureon (exenatide extended-release) product information and historical reporting (company materials). https://www.lilly.com/
[3] International Diabetes Federation. Global diabetes epidemiology and treatment context. https://diabetesatlas.org/